|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 243.82 USD | +0.51% |
|
-1.20% | +17.80% |
| 02:57pm | Johnson & Johnson Wins EU Approval for Akeega in BRCA-Mutated Prostate Cancer | MT |
| 11:09am | Johnson & Johnson Seeks Tecvayli Indication Extension in EU | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| JOHNSON & JOHNSON | Other Pharmaceuticals | +0.54% | -1.20% | +17.80% | +45.38% | +53.19% | 585B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- JNJ Stock
- Charts Johnson & Johnson
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition